



# Automated Extraction and PCR Platform Marketing & Support Status

For use in 2026 funding proposals by PHLs

Please note instrument marketing and support is dynamic situation. Information presented here reflects APHL’s best understanding as of March 1, 2025, but laboratories are encouraged to communicate directly with manufacturers for the most up to date information.

The platforms in Table 1 are FDA authorized as in vitro diagnostic (IVD) devices and are most likely to be considered by CDC in future assay development including new emergency use authorization (EUA) assays.

**Table 1. Automated platforms with IVD claims.**

	Platform	Marketing Status	Service/Reagent Support	CDC Assays
Roche	MagNA Pure 96	Available	Indefinite; <a href="#">public health pricing available</a>	<ul style="list-style-type: none"> <li>• Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>• Influenza (characterization panel)</li> <li>• Trioplex (EUA)</li> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> </ul>
	MagNA Pure 24	Available	Indefinite; <a href="#">public health pricing available</a>	<ul style="list-style-type: none"> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> <li>• LRN-B</li> </ul>
QIAGEN	EZ1 Advanced XL	Discontinued December 31, 2024	<a href="#">public health pricing available</a> Instrument support will be available until December 31, 2031	<ul style="list-style-type: none"> <li>• Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>• Influenza (characterization panel)</li> <li>• MERS Coronavirus (EUA)</li> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> <li>• LRN-B</li> </ul>
bioMérieux	NucliSENS® easyMag®	Discontinued; limited availability of refurbished systems	Limited support may still be available for some assays.	<ul style="list-style-type: none"> <li>• Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>• Influenza (characterization panel and H7 EUA)</li> <li>• MERS Coronavirus (EUA)</li> <li>• Trioplex (EUA)</li> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> </ul>
	EMAG®	Available	Indefinite	<ul style="list-style-type: none"> <li>• Influenza (characterization panel)</li> </ul>

Questions? Contact [infectious.diseases@aphl.org](mailto:infectious.diseases@aphl.org).



# Automated Extraction and PCR Platform Marketing & Support Status

For use in 2026 funding proposals by PHLs

The platforms in Table 2 are not FDA authorized IVD devices and less likely to be considered by CDC in future assay development including new EUA assays. These platforms were primarily authorized to address significant reagent supply chain issues during the COVID-19 response.

**Table 2. Automated platforms without IVD claims authorized for use with EUA assays.**

	Platform	Marketing Status	Service/Reagent Support	CDC Assays
QIAGEN	QIAcube <sup>1</sup>	Discontinued, Jan 1, 2019	Ends Jan 15, 2026	<ul style="list-style-type: none"> <li>Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>CDC DENV-1-4 Real-Time RT-PCR Assay</li> </ul>
	QIAcube HT	Available	Indefinite; <a href="#">public health pricing available</a>	<ul style="list-style-type: none"> <li>Influenza SARS-CoV-2 Multiplex (EUA)</li> </ul>
	QIAcube Connect	Available	Indefinite; <a href="#">public health pricing available</a>	Chemistries authorized for use with following assays allowing the platform to be used during COVID-19 response: <ul style="list-style-type: none"> <li>Influenza SARS-CoV-2 Multiplex (EUA)</li> </ul>
Thermo Fisher Scientific	KingFisher™ Flex Purification System	Available	Indefinite	<ul style="list-style-type: none"> <li>Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>Non-variola Orthopoxvirus Real-time PCR Assay</li> </ul>
	MagMAX Express-96 Deep Well Magnetic Particle Processor	Unavailable	Support is ending; will support if parts are available	<ul style="list-style-type: none"> <li>Ebola Virus NP Real-Time RT-PCR assay (EUA)</li> </ul>
Promega	Maxwell® RSC 48	Available	Indefinite; <a href="#">public health pricing available</a>	<ul style="list-style-type: none"> <li>Influenza SARS-CoV-2 Multiplex (EUA)</li> </ul>

<sup>1</sup> [https://www.aphl.org/programs/infectious\\_disease/Documents/QIAcube-Discontinuation%20letter\\_01-2019.pdf](https://www.aphl.org/programs/infectious_disease/Documents/QIAcube-Discontinuation%20letter_01-2019.pdf)



# Automated Extraction and PCR Platform Marketing & Support Status

For use in 2026 funding proposals by PHLs

Thermo Fisher Scientific discontinued selling the Applied Biosystems™ 7500 Fast Dx (ABI 7500 Fast Dx) at the end of 2022. They will continue to support the instrument through 2029. CDC completed an analysis of available thermocyclers in 2023 as described in this [summary report](#). CDC programs are currently evaluating the performance of CDC assays on several of the platforms outlined in the memo.

**Table 3. PCR Platforms with IVD claims authorized for use with EUA assays.**

	Platform	Marketing Status	Service/Reagent Support	CDC Assays
Thermo Fisher Scientific	ABI 7500 Fast Dx <sup>2</sup>	Discontinued December 2022	December 2029	<ul style="list-style-type: none"> <li>• Influenza SARS-CoV-2 Multiplex (EUA)</li> <li>• Influenza (characterization panel)</li> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> <li>• LRN-B</li> <li>• Trioplex (EUA)</li> <li>• MERS Coronavirus (EUA)</li> <li>• CDC DENV-1-4 Real-Time RT-PCR Assay</li> </ul>
	QuantStudio Dx (QSDX) <sup>3</sup>	Discontinued December 2023	December 2028	<ul style="list-style-type: none"> <li>• Influenza SARS-CoV-2 Multiplex (EUA) Trioplex (EUA)</li> <li>• Non-variola Orthopoxvirus Real-time PCR Assay</li> <li>• LRN-B</li> </ul>

<sup>2</sup> [https://www.aphl.org/programs/infectious\\_disease/Documents/7500FDX%20discontinuation\\_CDC\\_PHL\\_7yrs%20support\\_final.pdf](https://www.aphl.org/programs/infectious_disease/Documents/7500FDX%20discontinuation_CDC_PHL_7yrs%20support_final.pdf)

<sup>3</sup> [https://www.aphl.org/programs/infectious\\_disease/Documents/QuantStudio%20Dx%20instrument%20discontinuation%20customer%20letter-Global%5B37%5D%5B89%5D.pdf](https://www.aphl.org/programs/infectious_disease/Documents/QuantStudio%20Dx%20instrument%20discontinuation%20customer%20letter-Global%5B37%5D%5B89%5D.pdf)